B-Cell Malignancies | Special Reports

Updated Data for Pomalidomide in Relapsed/Refractory Multiple Myeloma

October 19, 2013

Clinical Articles

In an updated analysis of the phase III MM-003 trial, Celgene International Sarl, the makers of pomalidomide, reported on a new progression-free survival (PFS) analysis and final overall survival (OS) in September 2013.

Clinical Advances in Mantle Cell Lymphoma

October 19, 2013

Clinical Articles

The long-term prognosis for most patients with mantle cell lymphoma (MCL) is poor, with median overall survival rates of 3 to 5 years. Because treatment is not curative, almost all patients will experience a relapse or find that their disease is refractory to treatment.

Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?

October 18, 2013

Clinical Articles

A Q&A with Jennifer Brown MD, PhD, director of the Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, and assistant professor of Medicine at Harvard Medical School in Boston, MA.

Transforming Expectations and Outcomes With Targeted Therapies

October 18, 2013

Clinical Articles

With the arrival and incorporation into clinical practice of immunomodulatory drugs and proteasome inhibitor therapy, patients with multiple myeloma patients are achieving deep, durable responses and disease control, and are living longer

Addressing Challenges in Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma

October 18, 2013

Clinical Articles

Several oral drugs are in development for both non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL). “There is different activity in different lymphoma types with different oral drugs and antibodies in development,” said Andrew D. Zelenetz, MD, PhD.